Revenue, last quarter
$150.7M
+1.1% vs same quarter last year
Net income
−$19.4M
+29.3% vs same quarter last year
EPS, diluted
−$0.15
+31.8% vs same quarter last year
Operating cash flow
$15.8M
−63.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $642.8M | −$43.5M |
| FY24 | $610.8M | −$182.6M |
| FY23 | $618.7M | −$255.1M |
| FY22 | $516.4M | −$166M |
| FY21 | $490.5M | −$58.2M |
| FY20 | $298.8M | −$542.7M |
| FY19 | $245.9M | −$31.3M |
| FY18 | $146.3M | −$112.5M |
| FY17 | $71.1M | −$18.8M |
| FY16 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 69.1% | −9.5% | −6.8% |
| FY24 | 67.9% | −31.9% | −29.9% |
| FY23 | 66.2% | −42.9% | −41.2% |
| FY22 | 76.7% | −32.5% | −32.1% |
| FY21 | 84.9% | −10.7% | −11.9% |
| FY20 | 80.4% | −178.7% | −181.6% |
| FY19 | 75.2% | −12.4% | −12.7% |
| FY18 | 80.4% | −75.7% | −76.9% |
| FY17 | 85.1% | −25.8% | −26.4% |
| FY16 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $130.1M |
| FY24 | −$5.7M |
| FY23 | −$63.8M |
| FY22 | −$165.3M |
| FY21 | −$122.7M |
| FY20 | −$254.6M |
| FY19 | −$8.1M |
| FY18 | −$82.7M |
| FY17 | −$14.5M |
| FY16 | - |
- 10x Genomics
- Technology median
Show the numbers
| Year | 10x Genomics | Technology median |
|---|---|---|
| FY25 | −6.8% | −2.3% |
| FY24 | −29.9% | −5% |
| FY23 | −41.2% | −6.7% |
| FY22 | −32.1% | −4.4% |
| FY21 | −11.9% | −1.7% |
| FY20 | −181.6% | −3% |
| FY19 | −12.7% | 0% |
| FY18 | −76.9% | 0.8% |
| FY17 | −26.4% | 2% |
| FY16 | - | 2.3% |